UPDATE 1-Blackstone invests $2 bln in Alnylam, boosting gene-silencing drug development
Blackstone Group Inc said on
Monday it invested $2 billion in Alnylam Pharmaceuticals Inc
through an equity-and-debt deal, giving the drugmaker a
financial boost to develop its gene-silencing therapies.
Monday it invested $2 billion in Alnylam Pharmaceuticals Inc
through an equity-and-debt deal, giving the drugmaker a
financial boost to develop its gene-silencing therapies.
Posted by Reuters
